Use of topical antipsoriatic drugs in Denmark

A nationwide drug utilization study

Research output: Contribution to journalJournal articleResearchpeer-review

12 Downloads (Pure)

Abstract

Background: The reported real-life use of prescribed topical antipsoriatic drugs is conflicting and based on heterogeneous data sources. Objectives: To describe the utilization of topical antipsoriatic drugs among patients with psoriasis in Denmark. Methods: A drug utilization study was performed based on nationwide Danish health registry data. We identified patients who received a first-time hospital diagnosis of psoriasis and redeemed at least one topical drug prescription in the period 2005–2015 (n = 7743). Patients were followed for 3 years from the time of diagnosis. Use of topical and systemic antipsoriatic drugs was described, specified by the type of treatment. Results: The total use of topical drugs was divided between corticosteroids with calcipotriol (31%), calcipotriol (6·5%), very potent corticosteroids (24%), potent corticosteroids (30%), moderate corticosteroids (7·2%) and corticosteroids with antimicrobials (1·6%). There was a 19% reduction in the overall use of topical drugs during the study period. Use increased around the time of diagnosis and the majority of patients redeemed more than two packages of topical drugs during the first year after being diagnosed. Regional differences in patients’ use of topical drugs varied considerably. The distribution of use of topical drugs was uneven, with a minority of all patients (25%) using 70% of the total amount of topical treatment. There was a 70% increase in the use of methotrexate over the study period. Biologics were used by up to 6%. Conclusions: The study provides further evidence that the use of topical antipsoriatic drugs shows considerable heterogeneity over time and regional practices, and differences between patients.

Original languageEnglish
JournalBritish Journal of Dermatology
Volume180
Issue number1
Pages (from-to)157-164
ISSN0007-0963
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Drug Utilization
Denmark
Pharmaceutical Preparations
Adrenal Cortex Hormones
Psoriasis
Information Storage and Retrieval
Methotrexate
Registries

Cite this

@article{7ec22c29396342d085080f5273a5ba7b,
title = "Use of topical antipsoriatic drugs in Denmark: A nationwide drug utilization study",
abstract = "Background: The reported real-life use of prescribed topical antipsoriatic drugs is conflicting and based on heterogeneous data sources. Objectives: To describe the utilization of topical antipsoriatic drugs among patients with psoriasis in Denmark. Methods: A drug utilization study was performed based on nationwide Danish health registry data. We identified patients who received a first-time hospital diagnosis of psoriasis and redeemed at least one topical drug prescription in the period 2005–2015 (n = 7743). Patients were followed for 3 years from the time of diagnosis. Use of topical and systemic antipsoriatic drugs was described, specified by the type of treatment. Results: The total use of topical drugs was divided between corticosteroids with calcipotriol (31{\%}), calcipotriol (6·5{\%}), very potent corticosteroids (24{\%}), potent corticosteroids (30{\%}), moderate corticosteroids (7·2{\%}) and corticosteroids with antimicrobials (1·6{\%}). There was a 19{\%} reduction in the overall use of topical drugs during the study period. Use increased around the time of diagnosis and the majority of patients redeemed more than two packages of topical drugs during the first year after being diagnosed. Regional differences in patients’ use of topical drugs varied considerably. The distribution of use of topical drugs was uneven, with a minority of all patients (25{\%}) using 70{\%} of the total amount of topical treatment. There was a 70{\%} increase in the use of methotrexate over the study period. Biologics were used by up to 6{\%}. Conclusions: The study provides further evidence that the use of topical antipsoriatic drugs shows considerable heterogeneity over time and regional practices, and differences between patients.",
author = "Svendsen, {M T} and Ernst, {M T} and Andersen, {K E} and F Andersen and H Johannessen and A Potteg{\aa}rd",
note = "{\circledC} 2018 British Association of Dermatologists.",
year = "2019",
month = "1",
doi = "10.1111/bjd.17074",
language = "English",
volume = "180",
pages = "157--164",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "1",

}

Use of topical antipsoriatic drugs in Denmark : A nationwide drug utilization study. / Svendsen, M T; Ernst, M T; Andersen, K E; Andersen, F; Johannessen, H; Pottegård, A.

In: British Journal of Dermatology, Vol. 180, No. 1, 01.2019, p. 157-164.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Use of topical antipsoriatic drugs in Denmark

T2 - A nationwide drug utilization study

AU - Svendsen, M T

AU - Ernst, M T

AU - Andersen, K E

AU - Andersen, F

AU - Johannessen, H

AU - Pottegård, A

N1 - © 2018 British Association of Dermatologists.

PY - 2019/1

Y1 - 2019/1

N2 - Background: The reported real-life use of prescribed topical antipsoriatic drugs is conflicting and based on heterogeneous data sources. Objectives: To describe the utilization of topical antipsoriatic drugs among patients with psoriasis in Denmark. Methods: A drug utilization study was performed based on nationwide Danish health registry data. We identified patients who received a first-time hospital diagnosis of psoriasis and redeemed at least one topical drug prescription in the period 2005–2015 (n = 7743). Patients were followed for 3 years from the time of diagnosis. Use of topical and systemic antipsoriatic drugs was described, specified by the type of treatment. Results: The total use of topical drugs was divided between corticosteroids with calcipotriol (31%), calcipotriol (6·5%), very potent corticosteroids (24%), potent corticosteroids (30%), moderate corticosteroids (7·2%) and corticosteroids with antimicrobials (1·6%). There was a 19% reduction in the overall use of topical drugs during the study period. Use increased around the time of diagnosis and the majority of patients redeemed more than two packages of topical drugs during the first year after being diagnosed. Regional differences in patients’ use of topical drugs varied considerably. The distribution of use of topical drugs was uneven, with a minority of all patients (25%) using 70% of the total amount of topical treatment. There was a 70% increase in the use of methotrexate over the study period. Biologics were used by up to 6%. Conclusions: The study provides further evidence that the use of topical antipsoriatic drugs shows considerable heterogeneity over time and regional practices, and differences between patients.

AB - Background: The reported real-life use of prescribed topical antipsoriatic drugs is conflicting and based on heterogeneous data sources. Objectives: To describe the utilization of topical antipsoriatic drugs among patients with psoriasis in Denmark. Methods: A drug utilization study was performed based on nationwide Danish health registry data. We identified patients who received a first-time hospital diagnosis of psoriasis and redeemed at least one topical drug prescription in the period 2005–2015 (n = 7743). Patients were followed for 3 years from the time of diagnosis. Use of topical and systemic antipsoriatic drugs was described, specified by the type of treatment. Results: The total use of topical drugs was divided between corticosteroids with calcipotriol (31%), calcipotriol (6·5%), very potent corticosteroids (24%), potent corticosteroids (30%), moderate corticosteroids (7·2%) and corticosteroids with antimicrobials (1·6%). There was a 19% reduction in the overall use of topical drugs during the study period. Use increased around the time of diagnosis and the majority of patients redeemed more than two packages of topical drugs during the first year after being diagnosed. Regional differences in patients’ use of topical drugs varied considerably. The distribution of use of topical drugs was uneven, with a minority of all patients (25%) using 70% of the total amount of topical treatment. There was a 70% increase in the use of methotrexate over the study period. Biologics were used by up to 6%. Conclusions: The study provides further evidence that the use of topical antipsoriatic drugs shows considerable heterogeneity over time and regional practices, and differences between patients.

U2 - 10.1111/bjd.17074

DO - 10.1111/bjd.17074

M3 - Journal article

VL - 180

SP - 157

EP - 164

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -